Prof. Gal Markel

Clinical Microbiology and Immunology
School of Continuing Medical Education
Medicine Dean & Assoc. Deans
Clinical Departments
מיקרוביולוגיה ואימונולוגיה קלינית סגל אקדמי קליני
Quick navigation:
Prof. Gal Markel
Home Page
Gal Markel
PubMed
Linkedin profile

International Leader in Melanoma & Skin Cancer Immunotherapy

Prof Gal Markel is an internationally recognized oncologist that specializes in the treatment and consultation for melanoma and skin cancer patients. He is the director of the Davidoff Comprehensive Cancer Center and the Melanoma/Skin Cancers Center at Beilinson Hospital. His research is focused on the biology and immunology of melanoma and skin cancers.  

CV

Education

1996-2004      MD-PhD, Hadassah/Hebrew University Medical School. PhD with Highest Honors

2018-2020      MBA, Interdisciplinary Center Herzlia

Position in Tel Aviv University

2008-2010      Lecturer, Tumor Immunology, Gray Faculty of Medicine

2010-2014      Senior Lecturer, Tumor Immunology, Gray Faculty of Medicine

2014-2021     Associate Professor, Tumor Immunology, Gray Faculty of Medicine

2021-Present  Full Professor,  Immunology & Oncology, Gray Faculty of Medicine

Positions

2005-2008      Investigator, Ella Lemelbaum Institute for Melanoma

2008-2020      Chief Scientist, Ella Lemelbaum Institute for Melanoma

2012-2017      Residency in Medical Oncology, Institute for Oncology

2017-2020      Senior Oncologist, Ella Lemelbaum Institute for Melanoma

2020-2021      Director, Ella Lemelbaum Institute for Immuno-Oncology & Melanoma

2021-Present   Deputy Director General, Rabin Medical Center

                        Director, Davidoff Comprehensive Cancer Center

                        Director, Melanoma and Skin Cancers Center

2023-Present   Founder & Chairman, Samueli Integrative Cancer Pioneering Institute, Rabin Medical Center

2025-Present   Member, Supreme Academic Promotions Committee, Tel-Aviv University

Publications

  1. Markel G, Lieberman N, Katz G, Arnon TI, Lotem M, Drize O, Blumberg RS, Bar-Haim E, Mader R, Eisenbach L and Mandelboim O. CD66a interactions between human melanoma and NK cells: a novel class I MHC-independent inhibitory mechanism of cytotoxicity. J Immunol. 2002. 168: 2803-2810.
  2. Markel G, Seidman R, Stern N , Cohen-Sinai T, Itzhaki O, Katz G, Treves A, Besser M, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A and Schachter J. Inhibition of human Tumor Infiltrating Lymphocytes (TIL) effector functions by the homophilic Carcinoembryonic Cell Adhesion Molecule 1 (CEACAM1) interactions. J Immunol. 2006. 177: 6062-71.
  3. Markel G, Seidman R, Cohen Y, Besser MJ, Cohen Sinai T, Treves AJ, Orenstein A, Berger R and Schachter J. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack. Immunology. 2008 Jun 13. [Epub ahead of print]
  4. Markel G, Cohen-Sinai T, Besser MJ, Oved K, Itzhaki O, Seidman R, Treves AJ, Freidman E, Dotan Z, Keisari Y, Ramon J and Schachter J. Preclinical evaluation of Tumor Infiltrating Lymphocytes (TIL) adoptive transfer in melanoma patients. Anticancer Research. 2009. 29:145-154.
  5. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Schallmach E, Kubi E, Zabari N, Shalmon-Zifroni B, Hardan I, Catane R, Segal E, Markel G, Apter S, Kutshuk I, Nagler A and Schachter J. A phase II study using short term cultured or selected anti-tumor autologous lymphocytes following a non-myeloablative lympho depleting chemotherapy regimen in metastatic melanoma. 2009. J Immunotherapy. Apr 1. [Epub ahead of print].
  6. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ, Orenstein A, Nagler A and Schachter J. Matching of natural killer lysis receptors (NKLR) with NKLR-ligands as a novel approach for enhancing anti-melanoma activity of allogeneic NK cells. 2009. PLoS ONE. 4(5):e5597. Epub 2009 May 19.
  7. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser MJ Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J. Systemic dysregulation of CEACAM1 in the melanoma patients. Cancer Immunology Immunotherapy. Epub 2009 July 25.
  8. Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010. 16:2646-55.
  9. Markel G, Bar-Haim E, Zahavy E, Cohen H, Cohen O, Shafferman A, Velan B. The involvement of IL-17A in the murine response to sub-lethal inhalational infection with Francisella tularensis. PLoS One. 2010 Jun 18;5(6):e11176
  10. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zikich D, Hershkovitz L, Treves AJ, Shalmon B, Zippel D, Markel G, Shapira-Frommer R, Schachter J, Besser MJ. Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy. J Immunother. 2011. 34:212-20.
  11. Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G. Regulation of cancer aggressive features in melanoma cells by microRNAs. PLoS One. 2011. 6:e18936.
  12. Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G*, Eyal E*. Mutagen-specific mutation signature determines global microRNA binding. PLoS One. 2011;6(11):e27400.
  13. Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G*, Amer R*. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers. Invest Ophthalmol Vis Sci. 2011. 52:9368-72.
  14. Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions. Mol Cancer Ther. 2012. 11:1300-10.
  15. Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: a diagnostic and therapeutic target. Curr Top Med Chem. 2012;12(1):3-10.
  16. Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol. 2012;12:818214.
  17. Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol Immunother. 2012 61:1833-47.
  18. Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, Treves AJ, Markel G, Schachter J, Papa MZ. Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Exp Ther Med. 2012. 3:898-902.
  19. Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E, Schachter J, Besser MJ, Markel G. Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma. PLoS One. 2013;8(2):e57160.
  20. Besser MJ, Shoham T, Harari-Steinberg O, Zabari N, Ortenberg R, Yakirevitch A, Nagler A, Loewenthal R, Schachter J, Markel G. Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies. PLoS One. 2013;8(3):e57922.
  21. Hochberg M, Gilead L, Markel G, Nemlich Y, Feiler Y, Enk CD, Denichenko P, Karni R, Ingber A. Insulin-like growth factor-binding protein-7 (IGFBP7) transcript: A-to-I editing events in normal and cancerous human keratinocytes. Arch Dermatol Res. 2013. 305:519-28.
  22. Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013. 19:4792-800.
  23. Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J Clin Invest. 2013. 123:2703-18.
  24. Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levy D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G. A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study. Biomarkers. 2013 Sep;18(6):502-8.
  25. Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ. Adoptive T-cell transfer in melanoma. Immunotherapy. 2013. 5(1):79-90.
  26. Greenberg E, Nemlich Y, Markel G. MicroRNAs in cancer: lessons from melanoma. Curr Pharm Des. 2014;20(33):5246-59.
  27. Greenberg E, Hajdu S, Nemlich Y, Cohen R, Itzhaki O, Jacob-Hirsch J, Besser MJ, Schachter J, Markel G. Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex. Open Biol. 2014 Jun;4(6):140030. doi: 10.1098/rsob.140030.
  28. Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler Y, Zan-Bar I, Besser MJ, Azizi E, Eitan F, Schachter J, Markel G. CEACAM1 promotes melanoma cell growth through Sox-2. Neoplasia. 2014 May;16(5):451-60.
  29. Mossberg M, Vernick S, Ortenberg R, Markel G, Shacham-Diamand Y, Rishpon J. A Direct Electrochemical Detection Method of Melanoma Based on Melanoma Biomarker. Electroanalysis, Vol. 26, DOI: 10.1002/elan.201400150, 2014
  30. Zippel D, Barlev H, Ortenberg R, Barshak I, Schachter J, Markel G. A longitudinal study of CEACAM1 expression in melanoma disease progression. Oncol Rep, Vol. 33, pp 1314-8. 2015.
  31. Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Gordon Robertson A, Calin GA, Markel G, Fidler IJ, Bar-Eli M. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol. Vol. 7, pp. 311-21. 2015.
  32. Cohen R, Greenberg E, Nemlich Y, Schachter J, Markel G. miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1. Oncotarget. Vol. 6, pp. 19006-16, 2015
  33. Galore-Haskel G, Nemlich Y, Greenberg E, Ashkenazi S, Hakim M, Itzhaki O, Shoshani N, Shapira-Fromer R, Ben-Ami E, Ofek E, Anafi L, Besser MJ, Schachter J, Markel G. A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme. Oncotarget. Vol 6, pp. 28999-9015, 2015
  34. Ortenberg R, Sapoznik S, Zippel D, Shapira-Frommer R, Itzhaki O, Kubi A, Zikich D, Besser MJ, Schachter J, Markel G. Serum CEACAM1 elevation correlates with melanoma progression and failure to respond to adoptive cell transfer immunotherapy. J Immunol Res. 2015;2015:902137
  35. Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G. SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells. Oncotarget. Vol. 7, pp. 30166-77. 2016.
  36. Zippel D*, Markel G*, Shapira-Frommer R, Ben-Betzalel G, Goitein D, Ben-Ami E, Nissan A, Schachter J, Schneebaum S. Perioperative BRAF inhibitors in locally advanced stage III melanoma. J Surg Oncol. Vol. 116, pp. 856-861. 2017.
  37. Galore-Haskel G, Baruch EN, Berg A, Barshack I, Zilinksky I, Avivi C, Besser MJ, Schachter J, Markel G. Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma. Oncotarget. Vol. 8, pp. 99580-99586. 2017.
  38. Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O, Yunger S, Markel G, Schachter J, Besser MJ. Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation. Front Immunol. 2017 Oct 10;8:1211.
  39. Merhavi-Shoham E, Itzhaki O, Markel G, Schachter J, Besser MJ. Adoptive Cell Therapy for Metastatic Melanoma. Cancer J, 2017 Jan/Feb;23(1):48-53.
  40. Baruch EN, Berg AL, Besser MJ, Schachter J, Markel G. Adoptive T cell therapy: An overview of obstacles and opportunities. Cancer, Vol. 123, pp. 2154-2162, 2017
  41. Eisenberg V, Shamalov K, Meir S, Hoogi S, Sarkar R, Pinker S, Markel G, Porgador A, Cohen CJ. Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor. Front Immunol. 2017 Sep 29;8:1212.
  42. Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Shachter J, Shapira-Frommer and Markel G. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmun Rev. Vol. 17, pp. 284-289, 2018
  43. Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, Nemlich Y, Markel G. Regulation of CEACAM1 protein expression by the transcription factor ETS-1 in BRAF-mutant human metastatic melanoma. Neoplasia. Vol. 20, pp. 401-409, 2018
  44. Nemlich Y,  Baruch EN, Besser MJ,  Asher N, Shoshan E,   Bar-Eli M,  Anafi L, Barshack I, Schachter J,  Ortenberg R,  Markel G. ADAR1-Mediated Regulation of Melanoma Invasion. Nat Comm. Vol. 9, pp. 2154-2166, 2018
  45. Ben-Betzalel G Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G. Possible immune adverse-events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer. Vol. 101, pp. 229-234, 2018
  46. Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J,  Boursi B, Markel G. Clinical significance of anti PD-1 therapy induced pancreatic atrophy: A case-control study. Cancer Immunol Res 2018 Oct 1. pii: canimm.0659.2017.
  47. Boursi B, Werner TJ, Gholami S, Margalit O, Baruch E, Markel G, Eshet Y, Houshmand S, Shacham-Shmueli E, Mitchell TC, Mamtani R, Alavi A, Yang YX. Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Melanoma Res. 2018 Dec 14. doi: 10.1097 [Epub ahead of print]
  48. Ben-Betzalel G, Steinberg-Silman Y, Shtof R, Asher N, Shapira-Frommer R, Schachter J, Markel G. Immunotherapy comes of age in octagenarian and nonagenarian metastatic melanoma patients. Eur J Cancer 2019 Feb;108:61-68. 
  49. Asher N, Marom EM, Ben-Betzalel G, Baruch EN, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. Oncologist. 2019 May;24(5):640-647.
  50. Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits E, Baruch EN, Tripple V, Arama-Chayoth M, Greenberg E, Shenoy A, Ayasun R, Knafo N, Xu S, Anafi L, Yanovich-Arad G, Barnabas GD, Ashkenazi S, Besser MJ, Schachter J, Bosenberg M, Shadel GS, Barshack I, Kaech SM, Markel G*, Geiger T*. Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial Dependence. Cell. 2019 Sep 19;179(1):236-250.e18.
  51. Roszik J, Markovits E, Dobosz P, Layani A, Slabodnik-Kaner K, Baruch EN, Ben-Betzalel G, Grimm E, Berger R, Sidi Y, Schachter J, Shapira-Frommer R, Avni D, Markel G*, Leibowitz-Amit R*. TNFSF4 (OX40L) expression and survival in locally advanced and metastatic melanoma. Cancer Immunol Immunother. 2019 Sep;68(9):1493-1500.
  52. Bar J, Markel G, Gottfried T, Percik R, Leibowitz-Amit R, Berger R, Golan T, Daher S, Taliansky A, Dudnik E, Shulman K, Urban D, Onn A. Acute vascular events as a possibly related adverse event of immunotherapy: a single-institute melanoma retrospective study. Eur J Cancer. 2019 Oct;120:122-131.
  53. Zippel D, Friedman-Eldar O, Rayman S, Hazzan D, Nissan A, Schtrechman G, Markel G, Schachter J, Itzhaki O, Besser MJ. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma. Anticancer Res. 2019 Sep;39(9):4995-5001.
  54. Margolis N, Markovits E, Markel G. Reprogramming lymphocytes for the treatment of melanoma: From biology to therapy. Adv Drug Deliv Rev. 2019 Feb 15;141:104-12
  55. Zippel D, Yalon T, Nevo Y, Markel G, Asher N, Schachter J, Goitein D, Segal TA, Nissan A, Hazzan D. The non-responding adrenal metastasis in melanoma: The case for minimally invasive adrenalectomy in the age of modern therapies. Am J Surg. 2019 Nov 26. pii: S0002-9610(19)31547-8.
  56. Olteanu C, Scope A, Steinberg-Silman Y, Ziv M, Shear NH, Dodiuk-Gad RP, Markel G. Vemurafenib-induced DRESS/DIHS resulting in spontaneous melanoma regression: an immunological reaction shedding new light on melanoma treatment? Int J Dermatol. 2020 May;59(5):e139-e141.
  57. Besser MJ, Itzhaki O, Ben-Betzalel G, Zippel DB, Zikich D, Kubi A, Brezinger K, Nissani A, Levi M, Zeltzer LA, Ben-Nun A, Asher N, Shimoni A, Nagler A, Markel G, Shapira-Frommer R, Schachter J. Comprehensive single institute experience with melanoma TIL: Long term clinical results, toxicity profile, and prognostic factors of response. Mol Carcinog. 2020 Jul;59(7):736-744.
  58. Baruch EN, Ortenberg R, Avivi C, Anafi L, Dick-Necula D, Stossel C, Moshkovits Y, Itzhaki O, Besser MJ, Schachter J, Barshack I, Markel G. Immune co-culture cell microarray - a feasible tool for high-throughput functional investigation of lymphocyte-melanoma interactions. Oncoimmunology. 2020 Mar 25;9(1):1741267.
  59. Meirson T, Asher N, Bomze D, Markel G. Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation. Cancers (Basel). 2020 Jun 22;12(6):E1650.
  60. Meirson T, Bomze D, Markel G. Structural basis of SARS-CoV-2 spike protein induced by ACE2. Bioinformatics. 2020 Aug 20:btaa744. doi: 10.1093/bioinformatics/btaa744.
  61. Asher N, Ben-Betzalel G, Lev-Ari S, Shapira-Frommer R, Steinberg-Silman Y, Gochman N, Schachter J, Meirson T, Markel G. Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma. Cancers (Basel). 2020 Aug 18;12(8):E2329. doi: 10.3390/cancers12082329.
  62. Nemlich Y, Besser MJ, Schachter J, Markel G. ADAR1 regulates melanoma cell invasiveness by controlling beta3-integrin via microRNA-30 family members. Am J Can Res 2020 Aug 1;10(8):2677-2686.
  63. Bomze D, Asher N, Ali OH, Flatz L, Azoulay D, Markel G*, Meirson T*. The survival-inferred fragility of phase 3 clinical trials evaluating immune checkpoint inhibitors JAMA Network Open. 2020 Oct 1;3(10):e2017675.
  64. Galore-Haskel G, Greenberg E, Yahav I, Markovits E, Ortenberg R, Shapira-Fromer R,  Itzhaki O, Schachter J, Besser MJ, Markel G.  microRNA expression patterns in tumor infiltrating lymphocytes are strongly associated with response to adoptive cell transfer therapy. Cancer Immunol Immunother 2021 Jun;70(6):1541-1555
  65. Baruch EN, Youngster I, Ben-Betzalel G, Ortenberg R, Lahat A, Katz L, Adler K, Dick-Necula D, Raskin S, Bloch N, Rotin D, Anafi L, Avivi C, Melnichenko J, Steinberg-Silman Y, Mamtani R, Harati H, Asher N, Shapira-Frommer R, Brosh-Nissimov T, Eshet Y, Ben-Simon S, Ziv O, Khan MAW, Amit M, Ajami NJ, Barshack I, Schachter J, Wargo JA, Koren O, Markel G*, Boursi B*. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science. 2021 Feb 5;371(6529):602-609.
  66. Vishnevskia-Dai V, Rozner L, Berger R, Jaron Z, Elyashiv S, Markel G, Zloto O. Ocular side effects of novel anti-cancer biological therapies. Sci Rep. 2021 Jan 12;11(1):787.
  67. Beck L, Harel M, Yu S, Markovits E, Boursi B, Markel G, Geiger T. Clinical Proteomics of Metastatic Melanoma Reveals Profiles of Organ Specificity and Treatment Resistance. Clin Cancer Res. 2021 Apr 1;27(7):2074-2086. 
  68. de Azevedo RA, Shoshan E, Whang S, Markel G, Jaiswal AR, Liu A, Curran MA, Travassos LR, Bar-Eli M. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma. Oncoimmunology. 2020 Dec 6;9(1):1846915.
  69. Nissani A, Lev-Ari S, Meirson T, Jacoby E, Asher N, Ben-Betzalel G, Itzhaki O, Shapira-Frommer R, Schachter J, Markel G, Besser MJ. Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer. 2021 May;9(5):e001743.
  70. Gilboa S, Pras Y, Mataraso A, Bomze D, Markel G*, Meirson T*. Informative censoring of surrogate end-point data in phase 3 oncology trials. .Eur J Cancer. 2021 Aug;153:190-202.
  71. Asher N, Israeli-Weller N, Shapira-Frommer R, Ben-Betzalel G, Schachter J, Meirson T, Markel G. Immunotherapy Discontinuation in Metastatic Melanoma: Lessons from Real-Life Clinical Experience. Cancers (Basel). 2021 Jun 20;13(12):3074. 
  72. Meirson T, Bomze D, Markel G. Cytoreductive Surgery for Relapsed Ovarian Cancer. N Engl J Med. 2022 Mar 3;386(9):896-897.
  73. Margolis N, Moalem H, Meirson T, Galore-Haskel G, Markovits E, Baruch EN, Vizel B, Yeffet A, Kanterman-Rifman J, Debby A, Besser MJ, Schachter J, Markel G. Adenosine-Deaminase-Acting-on-RNA-1 Facilitates T-cell Migration toward Human Melanoma Cells. Cancer Immunol Res. 2022 Sep 1;10(9):1127-1140.
  74. Meirson T, Bomze D, Schueler-Furman O, Stemmer SM, Markel G. Systemic structural analysis of alterations reveals a common structural basis of driver mutations in cancer. NAR Cancer. 2023 Jan 18;5(1):zcac040.
  75. Tiosano A, Ben-Ishai M, Cnaany Y, Markel G, Kurman N, Popovtzer A, Bar Sela G, Ben Simon G, Gershoni A, Yassur I. Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration. Eye (Lond). 2023 Aug;37(12):2482-2487.
  76. Averbuch I, Salman S, Shtamper N, Doweck I, Popovtzer A, Markel G, Hendler D, Finkel I, Moore A, Fenig E, Taha T, Mhameed K, Kurman N, Billan S. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel. Front Oncol. 2023 Jan 26;13:1117804.
  77. Markovits E, Harush O, Baruch EN, Shulman ED, Debby A, Itzhaki O, Anafi L, Danilevsky A, Shomron N, Ben-Betzalel G, Asher N, Shapira-Frommer R, Schachter J, Barshack I, Geiger T, Elkon R, Besser MJ, Markel G. MYC Induces Immunotherapy and IFNγ Resistance in Melanoma Through Downregulation of JAK2. Cancer Immunol Res. 2023 Jul 5;11(7):909-924.
Tel Aviv University makes every effort to respect copyright. If you own copyright to the content contained
here and / or the use of such content is in your opinion infringing Contact us as soon as possible >>
Tel Aviv University, P.O. Box 39040, Tel Aviv 6997801, Israel